Moberg Pharma AB (publ) (STO:MOB)
10.12
+0.09 (0.90%)
Mar 25, 2026, 4:40 PM CET
Moberg Pharma AB Employees
Moberg Pharma AB had 5 employees as of December 31, 2025. The number of employees decreased by 5 or -50.00% compared to the previous year.
Employees
5
Change
-5
Growth
-50.00%
Revenue / Employee
2.71M SEK
Profits / Employee
-5.45M SEK
Market Cap
471.42M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | -5 | -50.00% |
| Sep 30, 2025 | 6 | -3 | -33.33% |
| Jun 30, 2025 | 9 | 0 | - |
| Mar 31, 2025 | 9 | 0 | - |
| Dec 31, 2024 | 10 | 0 | - |
| Sep 30, 2024 | 9 | 0 | - |
| Jun 30, 2024 | 9 | 0 | - |
| Mar 31, 2024 | 9 | 0 | - |
| Dec 31, 2023 | 10 | 3 | 42.86% |
| Sep 30, 2023 | 9 | 1 | 12.50% |
| Jun 30, 2023 | 9 | 1 | 12.50% |
| Mar 31, 2023 | 9 | 1 | 12.50% |
| Dec 31, 2022 | 7 | -1 | -12.50% |
| Sep 30, 2022 | 8 | 1 | 14.29% |
| Jun 30, 2022 | 8 | -3 | -27.27% |
| Mar 31, 2022 | 8 | -3 | -27.27% |
| Dec 31, 2021 | 8 | -3 | -27.27% |
| Sep 30, 2021 | 7 | -4 | -36.36% |
| Jun 30, 2021 | 11 | 0 | - |
| Mar 31, 2021 | 11 | -5 | -31.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Orexo AB | 72 |
| EQL Pharma AB | 55 |
| Cinclus Pharma Holding AB | 21 |
| Enzymatica AB | 20 |
| Nanexa AB | 15 |
| Cereno Scientific AB | 10 |
| Newbury Pharmaceuticals AB | 8 |
| Enorama Pharma AB | 5 |
Moberg Pharma AB News
- 5 months ago - Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential - PRNewsWire
- 1 year ago - Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU - PRNewsWire
- 1 year ago - Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients - PRNewsWire
- 1 year ago - Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98% - PRNewsWire